Ocular complications with the use of radium-223: a case series [PDF]
Radiation Oncology, 2022 Background Radium-223 is used for the treatment of osseous metastases in castrate-resistant prostate cancer, and has been shown to increase time to the first skeletal-related event, reduce the rate of hospitalization, and improve quality of life.
Julie R. Bloom +5 more
doaj +4 more sources
Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study [PDF]
Cancer Medicine, 2023 Background Radium‐233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium‐223 compared to best supportive care in ...
Anniina Hyväkkä +10 more
doaj +6 more sources
Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment [PDF]
Diagnostics, 2023 (1) Background: Prostate cancer is the second most common cancer in men, with androgen suppression as the standard treatment. Despite initially responding to castration, most metastatic prostate cancer patients eventually experience progression. In these
Elisabet Cantó +7 more
doaj +2 more sources
Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial [PDF]
, 2016 Symptomatic skeletal events (SSEs) commonly occur in patients with bone metastases, often leading to hospitalisations and decreased quality-of-life.
Christopher Parker +8 more
openalex +5 more sources
Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study [PDF]
Acta OncologicaBackground: The role and optimal sequencing of radium-223 in the treatment of metastatic castration-resistant prostate cancer (mCRPC) remain debated.
Charlotte Alverbratt +5 more
doaj +2 more sources
Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience [PDF]
Prostate International, 2019 Background: Treatment with radium-223 has been shown to increase survival and to delay skeletal events related to bone metastases of patients with metastatic Castration Resistant Prostate Cancer (mCRPC).
Renato P. Costa +7 more
doaj +3 more sources
Early use of abiraterone and radium-223 in metastatic prostate cancer [PDF]
, 2019 [No abstract ...
Elif Hindié, Clément Morgat
openalex +4 more sources
Drug Utilisation of Radium-223 Under Routine Clinical Practice (DIRECT) in Europe: A Post-Authorisation Safety Study [PDF]
Oncology and TherapyIntroduction Radium-223 is indicated for adults with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases, without visceral metastases, who progress after at least (≥) two lines of or are ineligible for other systemic ...
Rachel Weinrib +12 more
doaj +2 more sources
Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer [PDF]
Current OncologyIntroduction: Radium-223 dichloride (radium-223) is a bone-targeting radioisotope therapy that aids in the survival of patients with metastatic castration-resistant prostate cancer (mCRPC) to bones.
Colleen Mackenzie +9 more
doaj +2 more sources
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program [PDF]
BMC Cancer, 2019 Background Radium-223, a targeted alpha therapy, is used to treat symptomatic patients with castration-resistant prostate cancer (CRPC) and bone metastases. Data for radium-223 in asymptomatic CRPC patients with bone metastases are lacking.
Axel Heidenreich +11 more
doaj +3 more sources